JPMorgan Chase & Co. Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target increased by JPMorgan Chase & Co. from $35.00 to $39.00 in a research report released on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts also recently issued reports about the company. The Goldman Sachs Group upped their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Scotiabank dropped their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Citigroup dropped their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday. StockNews.com downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Syndax Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ:SNDX opened at $14.29 on Tuesday. The stock has a 50 day moving average of $14.31 and a 200 day moving average of $16.68. The company has a market cap of $1.22 billion, a PE ratio of -3.94 and a beta of 0.90. Syndax Pharmaceuticals has a 12-month low of $12.06 and a 12-month high of $25.16.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The company had revenue of $7.68 million during the quarter, compared to the consensus estimate of $86.32 million. Equities research analysts predict that Syndax Pharmaceuticals will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Neil Gallagher sold 4,618 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the sale, the insider now owns 85,095 shares in the company, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the sale, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. The trade was a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,683 shares of company stock worth $336,087. 4.10% of the stock is currently owned by insiders.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of SNDX. R Squared Ltd purchased a new stake in Syndax Pharmaceuticals during the 4th quarter valued at $26,000. Quantbot Technologies LP purchased a new stake in Syndax Pharmaceuticals during the 3rd quarter valued at $49,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares during the period. Virtus ETF Advisers LLC raised its holdings in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after buying an additional 827 shares during the period. Finally, Cape Investment Advisory Inc. raised its holdings in Syndax Pharmaceuticals by 157.1% during the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock valued at $85,000 after buying an additional 3,927 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).